Novel potent protein kinase C-related kinase 1 (PRK1) inhibitor with IC50 of 40±8.7 nM)

Negative control for GSK073

Antimalarial

Highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitor

Negative control for GSK8814

Selective glucocorticoid receptor agonist (SEGRA)

Novel agonist of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2)

Novel potent and selective BET pan-BD2 inhibitor

Negative control for GSK789

Novel Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor

Novel potent inhibitor of EchA6

Novel stabilizer of Zα 1 -antitrypsin, blocking Zα 1 -antitrypsin polymerisation in vitro, reducing intracellular polymerisation and increasing the secretion of Zα 1 -antitrypsin threefold in an iPSC model of disease

Negative control for GSK699

Novel PCAF/GCN5 degrader, modulating PCAF/GCN5 immune cell function through a PROTAC approach

Novel, soluble, permeable, and selective BRD7/9 inhibitor

Novel ATM inhibitor with cancer cell specific radiosensitization activity

Potent polo-like kinase 1 (PLK1) inhibitor

Novel inhibitor of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase

Novel potent EchA6 inhibitor

Novel highly potent and selective non-peptide oxytocin receptor antagonist

Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)

Novel, Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitor

Novel specific inhibitor of polo-like kinase 1 (PLK-1), inducing cell death by causing cell cycle arrest at G2/M phase by competing with the ATP binding site of PLK-1 thus leading to apoptosis

Negative control for GSK4027

First-in-Class GSK-3β/HDAC Dual Inhibitor as a Disease-Modifying Agent To Combat Alzheimer’s Disease

Potent and irreversible inhibitor of GSK3

Novel highly potent cell-permeable, reversible, ATP-competitive inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively)

Novel DNMT1-selective inhibitor (IC 50 = 0.11 ± 0.02 µM)

Novel anti-TB agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG, targeting MmpL3 and inhibiting EchA6

Novel inhibitor of prolyl hydroxylase (PHD) domain-containing enzyme